• Keros Therapeutics held its annual shareholder meeting on June 3, 2026.
• Shareholders selected Jean-Jacques Bienaimé, Charles Newton as directors, with terms running through the 2029 annual meeting.
• Shareholders ratified Deloitte & Touche as independent registered public accounting firm for fiscal 2026.
• Advisory vote on executive pay passed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001664710-26-000034), on June 03, 2026, and is solely responsible for the information contained therein.